Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Covid immunity through infection or vaccination: Are they equal?

Dr. Aaron Kheriaty, a University of California-Irvine psychiatry professor, felt he didn't need to be vaccinated against covid because he'd fallen ill with the disease in July 2020.

8 Oct 2021

Oral and intranasal COVID-19 vaccines show promising results in hamster model

A new preprint discusses the protective effect of an oral adenovirus-vectored vaccine based on the SARS-CoV-2 spike against viral transmission and disease in hamsters.

8 Oct 2021

Assay to assess and quantify presence of RBD-directed antibodies against SARS-CoV-2 following vaccination

Researchers from Roche Diagnostics have been testing a new assay known as the Elecsys assay.

8 Oct 2021

Adapting biological research and development to COVID-19

In this interview, News-Medical talks to Dr Yuning Chen, about the work he does with Sino Biological and how they have adapted their research & development to the COVID-19 pandemic.

From Sino Biological Inc. 8 Oct 2021

Scientists study immune response to COVID-19 in patients with different levels of disease severity

Researchers from Skoltech, U.S. companies VirIntel and Argentys Informatics, and two Russian Academy of Sciences institutes have studied the immune response to COVID-19 in patients with different levels of disease severity.

8 Oct 2021

Novel peptide-drug conjugate enhances the efficacy of immunotherapy in preclinical cancer models

A peptide-drug conjugate that targets the acidic environment of cancer cells enhanced the efficacy of immune checkpoint inhibitors in preclinical cancer models, according to results presented at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, held October 7-10, 2021.

7 Oct 2021

BNT162b2 COVID vaccine humoral response substantially reduced after 6 months

The rollout of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is expanding worldwide. However, little is known about the duration of protection offered by these vaccines. Real-world data on the kinetics of antibodies are beginning to appear, but a holistic picture of immunity duration is still not available.

7 Oct 2021

Critical function of IL-7 in diagnosis, prognosis, and treatment of COVID-19 patients

In this review, researchers summarized the therapeutic and pathogenic role of IL-7 in patients with COVID-19 and examined the promising role of IL-7 as a vaccine adjuvant.

7 Oct 2021

non-RBD mutation in SARS-CoV-2 variants enhances resistance to neutralizing antibodies

Researchers from Ohio State University have been investigating mutations in the rest of the spike protein, particularly the Q677H mutation.

7 Oct 2021

SARS-CoV-2 evolution promoted by long-term infection in patient with B cell depletion

A new study published on the medRxiv* preprint server focused on a patient with a persistent symptomatic viral infection for over a year. Researchers amplified sub-genomic transcripts for the E gene (sgE) using nasopharyngeal samples of the patient infected with SARS-CoV-2 over the course of 335 days.

6 Oct 2021

Study shows new antibody resistant variants can emerge in patients treated with monoclonal antibodies

A new study, published on the medRxiv* preprint server, suggested that selective pressures induced by the administration of monoclonal antibodies (Bamlanivimab) may require increased genomic surveillance to identify and control the spread of therapy-induced variants.

6 Oct 2021

Graphene biosensor in a portable and wireless device for rapid SARS-CoV-2 detection

A new study posted to the medRxiv* server and led by Dr. Mattia D'Agostino, Dr. Eleonora Pavoni and Dr. Alice Romagnoli from the Polytechnic University of Marche in Ancona (Italy), a gFET biosensor that uses angiotensin-converting enzyme 2 (ACE2) as a bioreceptor has been put forth as a viable solution.

6 Oct 2021

Moderna COVID vaccine booster dose results in immune memory

A recent study presents evidence that a booster dose of the Moderna vaccine can induce a robust memory immune response against COVID-19.

6 Oct 2021

Durability of immunity to SARS-CoV-2 reinfection

The current study used data on the durability of immunity among evolutionarily close coronavirus relatives of SARS-CoV-2 to estimate times to reinfection.

6 Oct 2021

Gene expression changes during acute SARS-CoV-2 infection may decide long-COVID symptoms

A team of US-based scientists has recently revealed the changes in gene expression profiles associated with the long-term consequences of COVID-19.

6 Oct 2021

SARS-CoV-2 emerging variants display enhanced syncytia formation

Researchers compared the replication and syncytia forming potential of Alpha, Beta, and D614G strains in human cell lines and primary airway cells.

6 Oct 2021

Study shows lower SARS-CoV-2 infection rates in smokers

Coronavirus disease 2019 (COVID-19) primarily infects the lungs, later spreading through the bloodstream. The worst prognoses are mostly seen in ‘at-risk’ groups, such as the immunocompromised, elderly, or those suffering from respiratory conditions.

6 Oct 2021

Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice

Researchers in the United States and China have developed plasmid DNA immunogens that induce effective antibody responses in mice against the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

5 Oct 2021

AstraZeneca COVID-19 vaccine safe and effective in phase 3 U.S., Chile, and Peru trial

A new study reports on the results of phase III clinical trial on the safety and efficacy of the AstraZeneca-Oxford COVID-19 vaccine.

5 Oct 2021

Anti-nucleocapsid SARS-Cov-2 antibodies wane over time in long-term care facilities

A new study shows that up to a third of survivors in LTCFs were infected during the first year after infection.

5 Oct 2021

Antibody News and Research

Further Reading

Covid immunity through infection or vaccination: Are they equal?

Oral and intranasal COVID-19 vaccines show promising results in hamster model

Assay to assess and quantify presence of RBD-directed antibodies against SARS-CoV-2 following vaccination

Adapting biological research and development to COVID-19

Scientists study immune response to COVID-19 in patients with different levels of disease severity

Novel peptide-drug conjugate enhances the efficacy of immunotherapy in preclinical cancer models

BNT162b2 COVID vaccine humoral response substantially reduced after 6 months

Critical function of IL-7 in diagnosis, prognosis, and treatment of COVID-19 patients

non-RBD mutation in SARS-CoV-2 variants enhances resistance to neutralizing antibodies

SARS-CoV-2 evolution promoted by long-term infection in patient with B cell depletion

Study shows new antibody resistant variants can emerge in patients treated with monoclonal antibodies

Graphene biosensor in a portable and wireless device for rapid SARS-CoV-2 detection

Moderna COVID vaccine booster dose results in immune memory

Durability of immunity to SARS-CoV-2 reinfection

Gene expression changes during acute SARS-CoV-2 infection may decide long-COVID symptoms

SARS-CoV-2 emerging variants display enhanced syncytia formation

Study shows lower SARS-CoV-2 infection rates in smokers

Plasmid DNA vaccines induce effective antibody responses against SARS-CoV-2 in mice

AstraZeneca COVID-19 vaccine safe and effective in phase 3 U.S., Chile, and Peru trial

Anti-nucleocapsid SARS-Cov-2 antibodies wane over time in long-term care facilities

eBook: End-to-end solutions for bispecific antibody development eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo